Nanorepro: Converting its CGM-distribution license into an equity stake - NuWays AG Research
Yesterday, NanoRepro announced the conversion of a distribution license covering a CGM-technology of FiberSense into a financial asset.
ANNONS
Introducing FiberSense's and its CGM technology. FiberSense is a health care technology company, developing continuous glucose monitoring (CGM) technology, which collects data on a user's glucose level through sensors and passes it on to smart phones or insulin pumps. Methods of this type have effectively replaced traditional blood sample approaches and are already the standard of care for type I diabetic patients in Germany.
Looking forward, we expect NanoRepro to maintain its strategic focus on growing its multi-brand consumer health platform. This growth is seen to be particularly driven by organic sales growth of Paedi Protect and newkee/DKW in the short-term. Given the right opportunity and commercial progress, we may also see further progress on NanoRepros clear and proven inorganic growth strategy from increases in existing equity stakes (i. e. through the majority option on hyped about science) and bolt-on acquisitions.
